Q32 Bio Inc (QTTB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Q32 Bio Inc (QTTB) has a cash flow conversion efficiency ratio of -0.137x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.34 Million) by net assets ($46.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Q32 Bio Inc (QTTB) liquidity interval to measure how many days the company can operate on defensive assets alone.
Q32 Bio Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Q32 Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Q32 Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Q32 Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Platform Group AG
XETRA:TPG
|
0.113x |
|
Aifeex Nexus Acquisition Corporation
NASDAQ:AIFE
|
-0.002x |
|
Mevaco S.A
AT:MEVA
|
0.028x |
|
Centro de Imagem Diagnósticos S.A
SA:AALR3
|
0.071x |
|
Awea Mechantronic Co Ltd
TW:1530
|
0.014x |
|
Sree Rayalaseema Hi-Strength Hypo Limited
NSE:SRHHYPOLTD
|
0.019x |
|
Hyosung Itx
KO:094280
|
-0.010x |
|
Y-Optics Manufacture Co. Ltd
KQ:066430
|
0.031x |
Annual Cash Flow Conversion Efficiency for Q32 Bio Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Q32 Bio Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Q32 Bio Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $42.01 Million | $-33.54 Million | -0.798x | +93.31% |
| 2024-12-31 | $5.67 Million | $-67.72 Million | -11.932x | -11786.26% |
| 2023-12-31 | $-182.92 Million | $-18.68 Million | 0.102x | +21.81% |
| 2022-12-31 | $-130.71 Million | $-10.96 Million | 0.084x | +112.96% |
| 2021-12-31 | $169.65 Million | $-109.75 Million | -0.647x | -34.41% |
| 2020-12-31 | $196.00 Million | $-94.33 Million | -0.481x | -36.19% |
| 2019-12-31 | $258.51 Million | $-91.36 Million | -0.353x | -63.04% |
| 2018-12-31 | $196.35 Million | $-42.56 Million | -0.217x | -428.91% |
| 2017-12-31 | $98.31 Million | $6.48 Million | 0.066x | +105.83% |
| 2016-12-31 | $7.50 Million | $-8.48 Million | -1.131x | -- |
About Q32 Bio Inc
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical t… Read more